

产品说明书

26 版

基本信息

产品编号:	R10022
产品名称:	雷西莫特

产品简介:

一种作用于 TLR7 和 TLR8 免疫反应调节剂, EC50 分别为 0.26 μ m 和 6.4 μ m。		
靶点:	TLR7	TLR8
体外研究:		
Resiquimod (R-848) 诱导半抗原和过敏原特异性循环 T 细胞 (包括 TH2 效应子) 产生 IFN- γ , 甚至丧失产生 IL-4 的能力。		
Resiquimod (R848) 以剂量依赖性方式增强 PBL 增殖, 并增加 BrdU 掺入试验中 BrdU 阳性细胞的数量。用 R848 处理的细胞表现出显著增加 (3.5 倍) 的荧光素酶 (NF- κ B 活性的报告分子) 活性。		
体内研究:		
Resiquimod 可用于动物建模, 构建小鼠细胞因子释放模型、免疫介导的心脏组织损伤模型。Resiquimod (R-848) (50 μ g/只, 肌肉注射途径) 显著上调在 SPF 鸡中 IFN- α 、IFN- β 、IFN- γ 、IL-1 β 、IL-4、iNOS 和 MHC-II 基因的表达。		
Resiquimod 的药代动力学特性的特点是半衰期短, 导致相关剂量下的 AUC 较低, 同时 Cmax 较高。		

使用方法 (供参考):

一: 体外实验			
DMSO: 溶于 DMSO (10mg/mL 加热至 60 °C)			
浓度 \ 质量 溶液体积	1mg	5mg	10mg
1 mM	3.1809 mL	15.9043 mL	31.8086 mL
5 mM	0.6362 mL	3.1809 mL	6.3617 mL
10 mM	0.3181 mL	1.5904 mL	3.1809 mL
储备液的保存方式: -80° C, 1 year; -20° C, 6 months。			
二: 体内实验			
1、请依序添加每种溶剂: 5% DMSO→40% PEG300→5% Tween-80→50% Saline Solubility: $\geq$ 2.5 mg/mL (7.95 mM); 澄清溶液			
2、请依序添加每种溶剂: 10% DMSO→40% PEG300→5% Tween-80→45% Saline Solubility: $\geq$ 2.08 mg/mL (6.62 mM); 澄清溶液 此方案可获得 $\geq$ 2.08 mg/mL (饱和度未知) 的澄清溶液。 以 1 mL 工作液为例, 取 100 μ L 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μ L PEG300 中, 混合均匀; 再向上述体系中加入 50 μ L Tween-80, 混合均匀; 然后再继续加入 450 μ L 生理盐水 定容至 1 mL。			



3、请依序添加每种溶剂： 10% DMSO→90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (6.62 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL (饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μ L 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μ L 20% 的 SBE-β-CD 生理盐水水溶液 中，混合均匀。

4、请依序添加每种溶剂： 10% DMSO→90% Corn Oil

Solubility: ≥ 2.08 mg/mL (6.62 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL (饱和度未知) 的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。

以 1 mL 工作液为例，取 100 μ L 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μ L 玉米油中，混合均匀。

注：工作液建议您现用现配，当天使用。

<1mg/ml 表示微溶或不溶。

普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

三、激酶实验

For luciferase assay, FG-9307 cells are transfected with the firefly NF- κ B-specific luciferase reporter vector pNF κ B-Met-Luc2. Transfection efficiency is monitored by co-transfection with the pSEAP2 control vector, which constitutively expresses the human secreted enhanced alkaline phosphatase (SEAP). Then the cells are treated with Resiquimod (R848, 1 μ g/mL), CQ (10 μ M), CQ plus R848 or PBS and incubated at 22°C for 24h. The culture medium of the transfectants is then analyzed for luciferase activity and SEAP activity using Luciferase Assay Kit and the Great EscAPE™ SEAP Chemiluminescence Detection Kit, respectively. The assay is performed three times.

四、细胞实验

For inhibition of lysosomal acidification, cells are incubated with 10 μ M CQ for 1h before Resiquimod (R848) treatment. After treatment, 20 μ L of 5mg/mL MTT is added to the plate. The plate is incubated at 22°C for 4h, and 200 μ L dimethyl sulfoxide is added to the plate to dissolve the reduced formazan. The plate is then read at 490nm with a microplate reader. To determine the effect of Myd88 inhibition on R848-induced cell proliferation, the Myd88 inhibitor Pepinh-MYD and the control peptide Pepinh-Control are added to PBL at the concentration of 50 μ M, and the plate is incubated at 22°C for 6h. After incubation, the cells are treated with R848 and subjected to MTT assay as above. To determine the effect of NF- κ B inactivation on R848-induced cell proliferation, BAY-11-7082, an irreversible inhibitor of I κ B- α phosphorylation, is added to the cells at the concentration of 1 μ M, and the plate is incubated at 22°C for 1h. After incubation, the cells are treated with R848 and subjected to MTT assay as earlier. All experiments are performed three times.

五、动物实验

A total of 40 SPF chickens of two-week old are allotted to one of the following four experimental groups (n=10/group): Group A: PBS control; Group B: inactivated NDV vaccine; Group C: commercial oil adjuvanted inactivated NDV vaccine prepared from lentogenic strain and Group D: combination of inactivated NDV vaccine and R-848 (50 μ g/bird). Vaccine or PBS is administered by intramuscular route in the thigh muscle. A booster dose is given 14-day post immunization (d. p. i). Two weeks post-booster, experimental SPF birds are challenged with velogenic strain of NDV (105 ELD50 per bird) intramuscularly. Clinical signs and mortality are observed daily till 14 day post-challenge (d. p. c). Cloacal swabs (n=6/group) are collected from the birds on day 0, 4, 7 and 14 post-challenge and inoculated into 10-day old embryonated chicken eggs (n=3 eggs/sample) through intra-allantoic route. Three day post-inoculation, the allantoic fluid is checked for the NDV growth by spot



haemagglutination using 10% chicken RBC.

注意事项:

- 1、为了您的安全和健康，请穿实验服并戴一次性手套操作。
- 2、以上信息仅做参考交流之用。

储存: -20° C

